Role of TRP Channels in Cancer-Induced Bone Pain.

Flaminia Coluzzi, Maria Sole Scerpa, Elisa Alessandri, Patrizia Romualdi, Monica Rocco
Author Information
  1. Flaminia Coluzzi: Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, 00189 Rome, Italy. ORCID
  2. Maria Sole Scerpa: Unit Anesthesia, Intensive Care and Pain Therapy, Sant'Andrea University Hospital, 00189 Rome, Italy. ORCID
  3. Elisa Alessandri: Unit Anesthesia, Intensive Care and Pain Therapy, Sant'Andrea University Hospital, 00189 Rome, Italy.
  4. Patrizia Romualdi: Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy. ORCID
  5. Monica Rocco: Department of Surgical and Medical Sciences and Translational Medicine, Sapienza University of Rome, 00189 Rome, Italy. ORCID

Abstract

The burden of cancer is growing in almost every country. Bone metastases significantly affect the prognosis and lead to an increase in mortality and morbidity. The management of cancer-induced bone pain (CIBP) still shows various unmet needs. Opioid use is burdened by a number of possible side effects. Moreover, recent progresses in cancer treatment significantly increased the life expectancy of cancer patients, even those with metastatic disease. In this narrative review, we reported the main findings regarding TRP channel function in cancer pain models. TRP cation channels play a key role in different functions of cancer cells, including the regulation of their potential for metastasization, and are the main channels involved in the pathways of pain perception, through peripheral and central effects. Genetic deletion decreased pain sensitivity following tumour cell inoculation. Preclinical data suggest a potential role for modulators of some TRP channels, such as TRPV1, TRPA1, TRPM7 and TRPM8. Clinical results are still scarce; however, the physiological role in modulating bone remodelling and the involvement of TRP channels in preclinical models of bone cancer pain have garnered interest as areas of research in the last few years, as innovative analgesic strategies that may overcome the long-term side effects of opioids.

Keywords

References

  1. Neurosci Lett. 2006 Jan 23;393(1):70-3 [PMID: 16243435]
  2. Front Endocrinol (Lausanne). 2022 Dec 16;13:1063815 [PMID: 36589815]
  3. Pulm Pharmacol Ther. 2021 Oct;70:102059 [PMID: 34302984]
  4. Eur J Pharmacol. 2021 Aug 5;904:174185 [PMID: 34015320]
  5. Nat Commun. 2023 Jun 30;14(1):3871 [PMID: 37391431]
  6. Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2677-84 [PMID: 25687976]
  7. Am J Med Genet A. 2018 Sep;176(9):1950-1955 [PMID: 30144375]
  8. J Pain. 2008 Aug;9(8):687-99 [PMID: 18455478]
  9. Immunology. 1990 Oct;71(2):196-201 [PMID: 1699880]
  10. Int J Biochem Cell Biol. 2012 Nov;44(11):1937-41 [PMID: 22835475]
  11. Neurosci Lett. 2023 Nov 1;816:137509 [PMID: 37802417]
  12. Front Immunol. 2022 Oct 05;13:1032294 [PMID: 36275706]
  13. Calcif Tissue Int. 2020 Jun;106(6):655-664 [PMID: 32140760]
  14. Biomolecules. 2023 Jun 13;13(6): [PMID: 37371563]
  15. Exp Mol Med. 2023 Aug;55(8):1757-1769 [PMID: 37524874]
  16. Eur J Pain. 2014 Jul;18(6):774-84 [PMID: 24827675]
  17. Biochim Biophys Acta Biomembr. 2022 Feb 1;1864(1):183782 [PMID: 34555418]
  18. Cell Death Dis. 2022 Mar 31;13(3):288 [PMID: 35361751]
  19. Eur J Med Chem. 2022 Aug 5;238:114435 [PMID: 35598411]
  20. Integr Cancer Ther. 2015 Jul;14(4):381-93 [PMID: 26100378]
  21. Int J Oncol. 2012 May;40(5):1431-40 [PMID: 22267123]
  22. J Neurosci. 2008 May 7;28(19):5072-81 [PMID: 18463260]
  23. Curr Top Membr. 2014;74:89-112 [PMID: 25366234]
  24. Sci Rep. 2017 Feb 22;7:42385 [PMID: 28225019]
  25. J Invest Dermatol. 2021 Aug;141(8):1964-1974 [PMID: 33675791]
  26. Bone. 2020 May;134:115272 [PMID: 32062002]
  27. Oncologist. 2023 Dec 11;28(12):e1268-e1278 [PMID: 37343145]
  28. Stem Cell Res Ther. 2019 Sep 23;10(1):284 [PMID: 31547874]
  29. Cell Death Discov. 2023 Jul 1;9(1):213 [PMID: 37393347]
  30. Carcinogenesis. 2014 Jul;35(7):1652-60 [PMID: 24743513]
  31. Int J Mol Sci. 2020 Jun 11;21(11): [PMID: 32545311]
  32. Pain. 2016 Nov;157(11):2605-2616 [PMID: 27482630]
  33. Mol Pain. 2012 Sep 27;8:75 [PMID: 23013719]
  34. Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1096-102 [PMID: 19617407]
  35. Nat Commun. 2021 May 17;12(1):2885 [PMID: 34001887]
  36. Br J Pharmacol. 2011 Aug;163(7):1479-94 [PMID: 21175579]
  37. Mol Pain. 2010 Jul 05;6:38 [PMID: 20602757]
  38. J Neurosci. 2007 Dec 12;27(50):13680-90 [PMID: 18077679]
  39. Front Pain Res (Lausanne). 2022 Nov 09;3:1022022 [PMID: 36438444]
  40. Mol Neurobiol. 2019 Jun;56(6):3854-3864 [PMID: 30215159]
  41. BMJ Open. 2023 Oct 21;13(10):e069908 [PMID: 37865405]
  42. J Exp Clin Cancer Res. 2021 Mar 16;40(1):100 [PMID: 33726758]
  43. Pain. 2005 Dec 15;119(1-3):225-232 [PMID: 16298071]
  44. J Pain Res. 2021 Nov 12;14:3521-3552 [PMID: 34795520]
  45. Int J Mol Sci. 2024 Sep 24;25(19): [PMID: 39408620]
  46. Int J Mol Sci. 2024 Jul 22;25(14): [PMID: 39063241]
  47. ACS Pharmacol Transl Sci. 2022 Sep 13;5(11):1119-1127 [PMID: 36407953]
  48. Temperature (Austin). 2015 Feb 11;2(2):214-26 [PMID: 27227025]
  49. Curr Oncol. 2022 Oct 27;29(11):8103-8120 [PMID: 36354700]
  50. Elife. 2018 Dec 18;7: [PMID: 30560783]
  51. Front Immunol. 2023 Sep 08;14:1232013 [PMID: 37744324]
  52. Life Sci. 2021 Jul 1;276:119469 [PMID: 33811892]
  53. Cancer Biol Ther. 2013 Feb;14(2):193-9 [PMID: 23254954]
  54. CNS Drugs. 2019 Oct;33(10):943-955 [PMID: 31578704]
  55. Pain. 2005 Sep;117(1-2):19-29 [PMID: 16043290]
  56. Cell Calcium. 2020 Jan;85:102111 [PMID: 31812825]
  57. J Pain Res. 2017 Apr 18;10:915-925 [PMID: 28458574]
  58. Pflugers Arch. 2021 Feb;473(2):151-165 [PMID: 32955611]
  59. J Pain Res. 2019 May 16;12:1553-1560 [PMID: 31190966]
  60. Protein Cell. 2017 Sep;8(9):644-661 [PMID: 28364279]
  61. Handb Exp Pharmacol. 2014;223:767-94 [PMID: 24961969]
  62. J Neurosci. 2013 Dec 4;33(49):19099-111 [PMID: 24305807]
  63. Anesthesiology. 2016 Oct;125(4):779-92 [PMID: 27428822]
  64. Curr Top Membr. 2022;89:221-246 [PMID: 36210150]
  65. Eur J Pharmacol. 2019 Sep 5;858:172475 [PMID: 31228456]
  66. Expert Opin Ther Targets. 2024 Oct;28(10):843-856 [PMID: 39450875]
  67. Pain. 2011 Oct;152(10):2267-2276 [PMID: 21737202]
  68. J Oral Biol Craniofac Res. 2023 Jan-Feb;13(1):71-77 [PMID: 36479039]
  69. J Immunol. 2020 Jan 15;204(2):280-285 [PMID: 31907270]
  70. Brain Res Rev. 2009 Apr;60(1):2-23 [PMID: 19203589]
  71. Front Oncol. 2023 Mar 16;13:1156618 [PMID: 37007073]
  72. Front Immunol. 2021 Dec 02;12:772941 [PMID: 34925342]
  73. Mol Pain. 2017 Jan;13:1744806917697008 [PMID: 28326936]
  74. Mol Med Rep. 2017 Aug;16(2):2009-2015 [PMID: 28656207]
  75. Int J Mol Sci. 2022 Feb 08;23(3): [PMID: 35163843]
  76. Int J Mol Sci. 2023 May 30;24(11): [PMID: 37298451]
  77. J Neurosci. 2005 Sep 28;25(39):8924-37 [PMID: 16192383]
  78. Pain. 2015 Jun;156(6):1018-1024 [PMID: 25659068]
  79. Front Mol Biosci. 2022 Aug 22;9:980262 [PMID: 36072430]
  80. Mol Pain. 2019 Jan-Dec;15:1744806919857981 [PMID: 31144562]
  81. Neuroimmunomodulation. 2009;16(5):300-17 [PMID: 19571591]
  82. Front Immunol. 2024 Feb 16;15:1335387 [PMID: 38433844]
  83. J Neurophysiol. 2019 Feb 1;121(2):427-443 [PMID: 30485151]
  84. Front Pharmacol. 2021 Aug 04;12:713944 [PMID: 34421611]
  85. Pharmacol Res. 2020 Feb;152:104576 [PMID: 31790822]
  86. J Anesth Analg Crit Care. 2024 Oct 11;4(1):70 [PMID: 39390585]
  87. Cancers (Basel). 2024 Feb 02;16(3): [PMID: 38339399]
  88. Cell Physiol Biochem. 2019;52(4):742-757 [PMID: 30933439]
  89. Biochem Biophys Res Commun. 2023 Mar 12;648:36-43 [PMID: 36724558]
  90. J Nanobiotechnology. 2022 Aug 13;20(1):378 [PMID: 35964037]
  91. Pain Physician. 2022 Nov;25(8):E1199-E1210 [PMID: 36375190]
  92. Mol Carcinog. 2017 Aug;56(8):1851-1867 [PMID: 28277613]
  93. Front Oncol. 2024 May 10;14:1392667 [PMID: 38800383]
  94. Pain. 2005 May;115(1-2):128-41 [PMID: 15836976]
  95. Physiol Rev. 2014 Jan;94(1):81-140 [PMID: 24382884]
  96. Ann Transl Med. 2020 Apr;8(7):482 [PMID: 32395526]
  97. J Neurosci. 2009 Jan 7;29(1):153-8 [PMID: 19129393]
  98. Nature. 2022 Nov;611(7935):405-412 [PMID: 36323780]
  99. Molecules. 2016 Jun 18;21(6): [PMID: 27322240]
  100. Br J Pharmacol. 2021 May;178(9):1995-2007 [PMID: 31724155]
  101. Curr Med Chem. 2011;18(20):3093-115 [PMID: 21651483]
  102. Cells. 2021 Dec 22;11(1): [PMID: 35011580]
  103. Cells. 2020 Jan 28;9(2): [PMID: 32013022]
  104. Brain Behav Immun. 2019 Jul;79:139-151 [PMID: 30685532]
  105. Mol Pain. 2012 Apr 03;8:24 [PMID: 22472208]
  106. Curr Osteoporos Rep. 2020 Jun;18(3):325-335 [PMID: 32249381]
  107. Ther Clin Risk Manag. 2015 Mar 31;11:515-23 [PMID: 25848298]
  108. Pain. 2017 Sep;158(9):1666-1677 [PMID: 28722693]
  109. J Nutr Sci Vitaminol (Tokyo). 2019;65(3):258-263 [PMID: 31257266]
  110. Antioxidants (Basel). 2023 Mar 10;12(3): [PMID: 36978936]
  111. J Biochem Mol Toxicol. 2024 Nov;38(11):e70026 [PMID: 39526508]
  112. Adv Pharmacol. 2017;79:173-198 [PMID: 28528668]
  113. Bone. 2022 May;158:115783 [PMID: 33276151]
  114. Int J Cancer. 2019 Jan 15;144(2):355-365 [PMID: 30289972]
  115. Front Cell Dev Biol. 2022 Apr 05;10:882578 [PMID: 35450292]
  116. Regul Pept. 2012 Nov 10;179(1-3):101-8 [PMID: 22982142]
  117. Int J Mol Sci. 2021 Jun 07;22(11): [PMID: 34200205]
  118. Curr Opin Neurobiol. 2022 Aug;75:102591 [PMID: 35728275]
  119. J Cancer. 2020 Jul 25;11(19):5678-5688 [PMID: 32913462]
  120. Eur J Pharmacol. 2020 Sep 5;882:173312 [PMID: 32610057]
  121. Temperature (Austin). 2022 May 29;10(1):50-66 [PMID: 37187829]
  122. Int J Mol Sci. 2019 Jul 10;20(14): [PMID: 31295806]
  123. Front Mol Neurosci. 2023 Aug 17;16:1239599 [PMID: 37664239]
  124. Neurol Res. 2019 Nov;41(11):972-979 [PMID: 31296147]
  125. eNeuro. 2018 May 30;5(3): [PMID: 29854941]
  126. Nat Rev Neurosci. 2017 Feb;18(2):73-85 [PMID: 28053327]
  127. Br J Anaesth. 2009 Feb;102(2):251-8 [PMID: 19038965]
  128. Mol Cancer Ther. 2011 Sep;10(9):1667-76 [PMID: 21750223]
  129. Cancer Rep (Hoboken). 2023 Dec;6(12):e1912 [PMID: 37867416]
  130. Front Cell Neurosci. 2018 Feb 15;12:38 [PMID: 29497363]
  131. Neuron. 2023 Apr 19;111(8):1301-1315.e5 [PMID: 36787749]
  132. Biomed Pharmacother. 2017 Jul;91:841-848 [PMID: 28501773]
  133. Sci Rep. 2021 Jan 21;11(1):2018 [PMID: 33479347]
  134. Front Oncol. 2021 May 10;11:667715 [PMID: 34041030]
  135. Br J Pharmacol. 2023 Nov;180(21):2750-2761 [PMID: 37350138]
  136. Front Cell Neurosci. 2023 Mar 30;17:1162874 [PMID: 37066077]
  137. Int J Mol Sci. 2023 Feb 26;24(5): [PMID: 36902007]
  138. Cells. 2021 Jun 21;10(6): [PMID: 34205555]
  139. Pain. 2009 Mar;142(1-2):27-35 [PMID: 19135797]
  140. J Neurosci. 2005 Mar 23;25(12):3126-31 [PMID: 15788769]
  141. Oncol Lett. 2018 Apr;15(4):4129-4136 [PMID: 29541177]
  142. Eur J Pain. 2015 Feb;19(2):152-8 [PMID: 24917026]
  143. Eur J Biochem. 2004 May;271(10):1827-34 [PMID: 15128293]
  144. Brain Sci. 2023 Apr 10;13(4): [PMID: 37190609]
  145. Oncol Rep. 2020 Dec;44(6):2547-2558 [PMID: 33125145]
  146. Int J Clin Exp Pathol. 2018 Nov 01;11(11):5149-5156 [PMID: 31949595]
  147. Chem Senses. 2013 Sep;38(7):563-75 [PMID: 23828908]
  148. Mol Biol Rep. 2022 Jan;49(1):577-585 [PMID: 34694549]
  149. J Bone Miner Metab. 2023 May;41(3):415-427 [PMID: 36715764]
  150. J Oncol. 2022 Oct 18;2022:6964550 [PMID: 36304985]
  151. Front Pharmacol. 2020 Apr 24;11:436 [PMID: 32390832]
  152. Front Neurol. 2022 Sep 21;13:936012 [PMID: 36212659]
  153. Int J Cancer. 2015 Sep 15;137(6):1475-83 [PMID: 25708385]
  154. Pain. 2008 Sep 15;138(3):604-616 [PMID: 18381233]
  155. J Neurosci. 2007 Feb 28;27(9):2331-7 [PMID: 17329430]
  156. FASEB J. 2024 Jun 15;38(11):e23731 [PMID: 38855909]
  157. Pflugers Arch. 2009 Oct;458(6):1093-102 [PMID: 19669158]
  158. Acta Pharm Sin B. 2022 May;12(5):2330-2347 [PMID: 35646518]
  159. Brain Res. 2003 Aug 8;980(2):293-6 [PMID: 12867271]
  160. Front Pain Res (Lausanne). 2021 Mar 22;2:638620 [PMID: 35295475]
  161. Handb Exp Pharmacol. 2009;(194):283-332 [PMID: 19655111]
  162. Sci Rep. 2016 Mar 17;6:23261 [PMID: 26983498]
  163. J Clin Invest. 2020 May 1;130(5):2527-2541 [PMID: 31999644]
  164. Br J Pharmacol. 2020 Jun;177(12):2683-2695 [PMID: 31985045]
  165. CNS Drugs. 2022 Jun;36(6):617-632 [PMID: 35616826]
  166. Hum Cell. 2024 Mar;37(2):394-407 [PMID: 38316716]
  167. Neuroscience. 2008 Feb 6;151(3):843-53 [PMID: 18178319]
  168. Anesthesiology. 2016 Jul;125(1):204-18 [PMID: 27176211]
  169. Pain. 2018 Mar;159(3):550-559 [PMID: 29351125]
  170. Front Pain Res (Lausanne). 2022 May 31;3:887747 [PMID: 35712449]
  171. Am J Physiol Cell Physiol. 2008 Aug;295(2):C293-5 [PMID: 18684990]
  172. Sci Rep. 2021 Feb 12;11(1):3730 [PMID: 33580126]
  173. J Cancer. 2016 Jun 08;7(10):1181-8 [PMID: 27390592]
  174. Pharmacol Res. 2015 Sep;99:194-201 [PMID: 26117426]
  175. J Bone Miner Metab. 2007;25(2):99-104 [PMID: 17323179]
  176. J Mol Endocrinol. 2018 Oct 15;61(4):207-218 [PMID: 30328352]
  177. Biomedicines. 2024 Sep 09;12(9): [PMID: 39335558]
  178. Oncotarget. 2017 Sep 11;8(45):78312-78326 [PMID: 29108231]
  179. Cell Tissue Res. 2014 Apr;356(1):77-82 [PMID: 24442491]
  180. Naunyn Schmiedebergs Arch Pharmacol. 2005 Apr;371(4):285-94 [PMID: 15889240]
  181. Invest Ophthalmol Vis Sci. 2016 Nov 1;57(14):6447-6454 [PMID: 27893109]
  182. Bone Res. 2020 Jul 29;8(1):30 [PMID: 32793401]
  183. Neurosci Bull. 2012 Apr;28(2):165-72 [PMID: 22466127]
  184. Pflugers Arch. 2013 Jun;465(6):853-64 [PMID: 23271453]
  185. Front Pharmacol. 2016 Jun 23;7:178 [PMID: 27445816]
  186. Life Sci. 2021 May 1;272:119259 [PMID: 33636172]
  187. Biochim Biophys Acta. 2007 Aug;1772(8):879-84 [PMID: 17560087]
  188. Cancers (Basel). 2019 Dec 17;11(12): [PMID: 31861097]
  189. Front Pharmacol. 2019 Oct 18;10:1253 [PMID: 31680989]
  190. Cell Death Dis. 2024 Aug 27;15(8):624 [PMID: 39191723]
  191. PLoS One. 2010 Apr 21;5(4):e10234 [PMID: 20422007]
  192. Anesthesiology. 2016 May;124(5):1153-65 [PMID: 26859646]
  193. J Med Chem. 2005 Mar 24;48(6):1857-72 [PMID: 15771431]
  194. Kidney Int. 2019 Dec;96(6):1283-1291 [PMID: 31471161]
  195. Korean J Intern Med. 2017 Nov;32(6):1069-1074 [PMID: 28103434]
  196. Biochim Biophys Acta Rev Cancer. 2022 Nov;1877(6):188828 [PMID: 36283598]
  197. Anesthesiology. 2011 Jun;114(6):1425-34 [PMID: 21502857]
  198. Pain Ther. 2022 Jun;11(2):477-491 [PMID: 35122615]
  199. Gastroenterology. 2011 Apr;140(4):1283-1291.e1-2 [PMID: 21185837]
  200. J Exp Clin Cancer Res. 2016 Jul 21;35(1):116 [PMID: 27439311]
  201. J Anesth. 2010 Apr;24(2):328-32 [PMID: 20372938]
  202. Curr Top Med Chem. 2011;11(17):2171-9 [PMID: 21671877]
  203. Oncol Rep. 2015 Sep;34(3):1449-59 [PMID: 26133236]
  204. Bone. 2023 Jan;166:116579 [PMID: 36210025]
  205. Adv Exp Med Biol. 2024;1461:3-13 [PMID: 39289270]
  206. Mol Pain. 2005 Jan 17;1:3 [PMID: 15813989]
  207. Mol Pain. 2010 Dec 01;6:85 [PMID: 21118579]
  208. J Dent Res. 2016 Aug;95(9):1057-64 [PMID: 27084672]
  209. Curr Neuropharmacol. 2024;22(1):6-14 [PMID: 37559537]
  210. Signal Transduct Target Ther. 2023 Jul 5;8(1):261 [PMID: 37402746]
  211. J Endocrinol Invest. 2018 Dec;41(12):1377-1388 [PMID: 30343356]
  212. Front Pharmacol. 2023 Mar 22;14:1098448 [PMID: 37033630]
  213. Neuroscience. 2007 Aug 24;148(2):560-72 [PMID: 17656027]
  214. Prog Drug Res. 2014;68:77-104 [PMID: 24941665]
  215. BMC Cancer. 2018 Nov 26;18(1):1167 [PMID: 30477473]
  216. Inflammopharmacology. 2023 Dec;31(6):3153-3166 [PMID: 37752305]
  217. Front Immunol. 2020 Nov 25;11:585880 [PMID: 33324405]
  218. Cancer Res. 2017 Mar 15;77(6):1283-1295 [PMID: 28254863]
  219. Oncol Lett. 2022 Apr;23(4):108 [PMID: 35242236]
  220. Neurosci Lett. 2013 Dec 17;557 Pt A:52-9 [PMID: 24076008]
  221. Int J Mol Med. 2016 Dec;38(6):1905-1914 [PMID: 27840893]
  222. Int J Mol Sci. 2024 Mar 28;25(7): [PMID: 38612571]
  223. Cancers (Basel). 2020 Apr 25;12(5): [PMID: 32344908]
  224. Sci Rep. 2019 Feb 26;9(1):2769 [PMID: 30808963]
  225. Pharmaceuticals (Basel). 2019 Feb 02;12(1): [PMID: 30717379]
  226. Theranostics. 2019 Jun 9;9(15):4461-4473 [PMID: 31285773]
  227. Mol Pharmacol. 2001 Jan;59(1):9-15 [PMID: 11125018]
  228. FASEB J. 2015 Jan;29(1):182-92 [PMID: 25351988]
  229. Clin Auton Res. 2021 Apr;31(2):165-178 [PMID: 32926324]
  230. Nat Rev Drug Discov. 2024 Oct;23(10):780-796 [PMID: 39242781]
  231. Pharmacol Rep. 2020 Oct;72(5):1418-1425 [PMID: 32715433]
  232. J Bone Miner Metab. 2018 May;36(3):274-285 [PMID: 28516219]
  233. Biomolecules. 2021 Dec 21;12(1): [PMID: 35053150]
  234. Life Sci. 2022 Feb 15;291:120305 [PMID: 35016880]
  235. Pain. 2015 Jun;156(6):1124-1144 [PMID: 25775359]
  236. Int J Mol Sci. 2024 May 27;25(11): [PMID: 38892000]

MeSH Term

Humans
Transient Receptor Potential Channels
Bone Neoplasms
Cancer Pain
Animals

Chemicals

Transient Receptor Potential Channels

Word Cloud

Created with Highcharts 10.0.0cancerpainTRPchannelsboneeffectsroleBonesignificantlystillsidemainmodelspotentialTRPV1TRPA1TRPM8opioidsburdengrowingalmosteverycountrymetastasesaffectprognosisleadincreasemortalitymorbiditymanagementcancer-inducedCIBPshowsvariousunmetneedsOpioiduseburdenednumberpossibleMoreoverrecentprogressestreatmentincreasedlifeexpectancypatientsevenmetastaticdiseasenarrativereviewreportedfindingsregardingchannelfunctioncationplaykeydifferentfunctionscellsincludingregulationmetastasizationinvolvedpathwaysperceptionperipheralcentralGeneticdeletiondecreasedsensitivityfollowingtumourcellinoculationPreclinicaldatasuggestmodulatorsTRPM7Clinicalresultsscarcehoweverphysiologicalmodulatingremodellinginvolvementpreclinicalgarneredinterestareasresearchlastyearsinnovativeanalgesicstrategiesmayovercomelong-termRoleChannelsCancer-InducedPainmetastasisneuropathicresiniferatoxin

Similar Articles

Cited By